Updated report of a phase II randomized trial of transoral surgical resection followed by low-dose or standard postoperative therapy in resectable p16+ locally advanced oropharynx cancer: A trial of the ECOG-ACRIN cancer research group (E3311).
Robert L. Ferris(University of Pittsburgh), Barbara Burtness(Yale University), Harry Quon(Johns Hopkins University), Jolie Ringash(University Health Network), Wayne M. Koch(Johns Hopkins University), Nabil F. Saba(Emory University), Jan S. Lewin(The University of Texas MD Anderson Cancer Center), Joaquín J. García(Mayo Clinic), Ranee Mehra(University of Maryland, Baltimore), R. Bryan Bell(Takara (United States)), Umamaheswar Duvvuri(City University of New York), Giovana R. Thomas(National Institutes of Health), Bert W. O’Malley(Baylor College of Medicine), Lynne I. Wagner(University of North Carolina at Chapel Hill), Miriam N. Lango(Fox Chase Cancer Center), Shuli Li(Unknown), Gregory S. Weinstein(University of Pennsylvania), Michael E. Kupferman(The University of Texas MD Anderson Cancer Center), Enver Özer(The Ohio State University Wexner Medical Center), Yael Flamand(Dana-Farber Cancer Institute)
Cited by 26
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in <i>NOTCH1</i>
|Science|2011|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
Cancer-Related Fatigue, Version 2.2015
|Journal of the National Comprehensive Cancer Network|2015|951